Clinical Trial Update: Sapphire 3 CTO Study [NA]

View source ↗

Summary

OrbusNeich reports that the Sapphire 3 CTO study has completed; the update provides status with no efficacy results shared.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arteriosclerosis
• Cardiovascular Diseases
• Coronary Artery Disease
• Myocardial Ischemia
• Total Occlusion of the Coronary Artery

Snippet

Sponsor: OrbusNeich | Conditions: Coronary Artery Disease, Coronary Disease | NA | Status: COMPLETED